Pancreatic Cancer | Specialty

Dr Sundaresan on Reasons Why Patients With Pancreatic Cancer May Decline Treatment

July 10th 2024

Tilak Sundaresan, MD, on results of a retrospective study of reasons why patients with pancreatic cancer decline treatment.

The Role of mTOR/Aurora A Kinase Combination Therapy Requires Further Elucidation in Solid Tumors

July 5th 2024

S. Lindsey Davis, MD, highlights data with the mTOR inhibitor sapanisertib and Aurora A kinase inhibitor alisertib in patients with solid tumors.

Dr Evans on the Influence on Patient Factors and Treatment Decisions in Pancreatic Cancer

July 2nd 2024

Nicole S. Evans, MD, discusses the influence of patient factors on declining treatment in pancreatic cancer.

Mitazalimab/mFOLFIRINOX Is Tolerable, Generates Responses in Treatment-Naive mPDAC

July 2nd 2024

Mitazalimab plus mFOLFIRINOX yielded early efficacy signals and a manageable safety profile for the frontline treatment of patients with mPDAC.

MPO Could Represent Predictive OS Biomarker for CM24 Plus Nivolumab/Chemo in Second-Line PDAC

June 27th 2024

MPO may be a predictive biomarker for survival for treatment with CM24, nivolumab, and chemotherapy in second-line pancreatic ductal adenocarcinoma.

Mitazalimab Plus mFOLFIRINOX Yields 18-Month OS Benefit in Previously Untreated Metastatic Pancreatic Cancer

June 26th 2024

Frontline mitazalimab plus mFOLFIRINOX generated an OS benefit and prolonged DOR in patients with metastatic pancreatic ductal adenocarcinoma.

Dr Garcia-Carbonero on the Phase 2b VIRAGE Trial in Metastatic PDAC

June 24th 2024

Rocio Garcia-Carbonero, MD, discusses the rationale for the phase 2b VIRAGE trial in patients with metastatic pancreatic cancer.

Addition of XB2001 to Chemo Improves Safety in Advanced Pancreatic Cancer

June 20th 2024

XB2001 plus chemotherapy improved safety and was tied to a trend toward improved overall survival in pretreated advanced pancreatic cancer.

Poised Potential With Zenocutuzumab in NRG1+ Pancreatic Cancer

June 14th 2024

E. Gabriela Chiorean, MD, of Fred Hutch Cancer Center, discusses the recent clinical data with zenocutuzumab in patients with NRG1 fusion–positive pancreatic cancer and the impact the approval of this agent could have on the landscape.

Standard Treatment Regimens for NRG1+ Pancreatic Cancer

June 14th 2024

E. Gabriela Chiorean, MD, of Fred Hutch Cancer Center, discusses current standard therapeutics for patients with NRG1 fusion–positive pancreatic cancer.

Choosing RNA Over DNA Testing for NRG1 Fusions in Pancreatic Cancer

June 14th 2024

E. Gabriela Chiorean, MD, of Fred Hutch Cancer Center, discusses the benefits and challenges of DNA and RNA testing for NRG1 fusions in patients with pancreatic cancer.

Prognosis, Rarity of NRG1+ Pancreatic Cancer

June 14th 2024

E. Gabriela Chiorean, MD, of Fred Hutch Cancer Center, discusses prognosis and rarity of patients with NRG1 fusion–positive pancreatic cancer.

IBI343 Receives FDA Fast Track Designation for Advanced/Metastatic PDAC

June 13th 2024

The FDA granted fast track designation to IBI343 monotherapy for relapsed/refractory advanced unresectable or metastatic pancreatic ductal adenocarcinoma.

Dr Huffman on the Investigation of Azenosertib Plus Gemcitabine in Advanced Pancreatic Cancer

June 11th 2024

Brandon Huffman, MD, discusses an ongoing phase 2 trial evaluating azenosertib plus gemcitabine in advanced pancreatic cancer.

Dr Kamath on the Tumor Microbiome of Early- and Average-Onset PDAC

June 10th 2024

Suneel Kamath, MD, discusses tumor microbiome differences between early-onset and average-onset pancreatic adenocarcinoma.

Exploring the Nuances of Postoperative Considerations in Pancreatic Cancer

June 5th 2024

Zyed Nabeel Zafar, MD, MPH, explores the nuances of postoperative considerations in pancreatic cancer treatment.

Pitavastatin Offers Therapeutic Potential in Cancers Arising From Chronic Inflammation

May 30th 2024

Pitavastatin, an FDA-approved statin, may inhibit pathways that contribute to IL-33 production, which has been shown to contribute to cancer development.

Dr Lim on Multidisciplinary Approaches to Pancreatic Cancer Management

May 23rd 2024

Kian-Huat Lim, MD, PhD, discusses the importance of multidisciplinary collaboration when diagnosing and treating patients with pancreatic cancer.

FDA Grants Fast Track Designation to VCN-01 in Metastatic Pancreatic Cancer

May 23rd 2024

VCN-01 plus gemcitabine and nab-paclitaxel has received fast track designation from the FDA in metastatic pancreatic adenocarcinoma.

FDA Grants Orphan Drug Designation to Azeliragon for Pancreatic Cancer

May 21st 2024

The FDA has granted orphan drug designation to azeliragon as a potential therapeutic option for patients with pancreatic cancer.